Author Archive: AZBio

NIH Announces New Indirect Cost Rates of 15%

Posted on by

NIH announced on February 7, 2025 that effective Monday, February 10, 2025,  “In accordance with 45 CFR 75 and its accompanying appendices, this Guidance implements and makes publicly available NIH’s updated policy deviating from the negotiated indirect cost rate for new grant awards and existing grant awards, effective as of the date of this Guidance’s issuance. Pursuant to this Supplemental Guidance, there will be a standard indirect rate of 15% across all NIH grants for indirect costs in lieu of a separately negotiated rate for indirect costs in every grant.”

Read Notice Number NOT-OD-25-068 for more information.Continue reading→

Finance Committee Members Introduce Bipartisan Legislation to Ensure Medicare Patients’ Access to Cancer Detection Technologies

Posted on by

Washington, D.C.–U.S. Senate Finance Committee Chairman Mike Crapo (R-Idaho) and Finance Committee member Michael Bennet (D-Colorado), with Ranking Member Ron Wyden (D-Oregon) and Finance Committee member Tim Scott (R-South Carolina), reintroduced the Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act that would ensure Medicare beneficiaries’ access to cutting-edge tests capable of detecting multiple types of cancer before symptoms appear. Bipartisan companion legislation (H.R. 842) was also introduced in the U.S. House of Representatives. Continue reading→

XLR8 PBC Applications Open for Scale-Ready Health Tech Companies; Esteemed Mentor Lineup Announced

Posted on by

Phoenix, AZ – XLR8 PBC, Arizona’s premier program for scale-ready health tech companies, is now accepting applications for its latest cohort. With a no-cost, no-equity structure, XLR8 PBC provides health tech companies with unparalleled access to industry leaders, mentorship, and strategic resources. Applications for the program are open until February 19, 2025, offering founders the opportunity to engage with a world-class team of mentors and position their ventures for accelerated growth.Continue reading→

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Posted on by

— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years —

— JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain —Continue reading→

Clinical study explores regenerative therapy for epilepsy

Posted on by

Mayo Clinic is participating in the first in-human investigation of regenerative therapy for the treatment of drug-resistant epilepsy. The multicenter study will test the safety of implanting interneurons into the hippocampus in patients with the disease. Future studies are planned to investigate the potential for these cells to restore normal excitatory-inhibitory balance.Continue reading→